Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China (mainland).
Med Sci Monit. 2020 Feb 17;26:e921649. doi: 10.12659/MSM.921649.
BACKGROUND Glucocorticoids are important components of a number of chemotherapeutic regimens used to treat pediatric acute lymphoblastic leukemia (ALL). A primary cause of treatment failure of ALL is acquired resistance to glucocorticoids. Recently, traditional Chinese medicines were effectively used to treat solid tumors. Thus, the aim of this study was to investigate whether Huai Qi Huang (HQH), a traditional Chinese medicine, increased the efficacy of glucocorticoids in the treatment of ALL, and if so, to determine the underlying mechanism. MATERIAL AND METHODS Various concentrations of HQH were used to treat Jurkat and Nalm-6 cells for 24 to 72 hours. Subsequently, cells were co-treated with HQH and the glucocorticoid receptor agonist, dexamethasone (DEX), or a MEK inhibitor (PD98059) to verify the synergistic effects on apoptosis in Jurkat and Nalm-6 cells for 24 hours. Cell Counting Kit-8 assay and flow cytometry were used to measure cell viability and apoptosis, respectively. Protein and mRNA expression levels were assessed using western blotting and quantitative polymerase chain reaction. RESULTS The results revealed that cell survival was reduced and apoptosis was increased as the HQH concentration was increased, and this was accompanied with increases in the levels of BAX, cleaved-caspase-3 and glucocorticoid receptor alpha (GRalpha) and decreases in the levels of Bcl-2 and phospho-ERK (pERK). Glucocorticoid receptor ß (GRß) and total ERK (t-ERK) had no significant changes. Combined treatment with HQH and DEX or PD98059 increased apoptosis in Jurkat and Nalm-6 cells, and concurrently increased BAX, cleaved-caspase-3, GILZ, NFKBIA, and GRalpha and decreased Bcl-2 and pERK. CONCLUSIONS HQH enhanced the sensitivity of ALL cells to glucocorticoids by increasing the expression of GRalpha and inhibiting the MEK/ERK pathway, thus providing a rational foundation for the treatment of ALL with HQH.
糖皮质激素是治疗小儿急性淋巴细胞白血病(ALL)的许多化疗方案中的重要组成部分。ALL 治疗失败的一个主要原因是对糖皮质激素产生获得性耐药。最近,传统中药已被有效地用于治疗实体瘤。因此,本研究旨在探讨传统中药槐杞黄(HQH)是否能提高糖皮质激素治疗 ALL 的疗效,如果是,确定其潜在机制。
用不同浓度的 HQH 处理 Jurkat 和 Nalm-6 细胞 24 至 72 小时。随后,用 HQH 与糖皮质激素受体激动剂地塞米松(DEX)或 MEK 抑制剂(PD98059)共处理细胞 24 小时,以验证对 Jurkat 和 Nalm-6 细胞凋亡的协同作用。细胞计数试剂盒-8 检测法和流式细胞术分别用于测量细胞活力和凋亡。采用 Western blot 和实时定量聚合酶链反应评估蛋白和 mRNA 表达水平。
结果表明,随着 HQH 浓度的增加,细胞存活率降低,凋亡增加,同时 BAX、cleaved-caspase-3 和糖皮质激素受体α(GRalpha)水平升高,Bcl-2 和磷酸化 ERK(pERK)水平降低。糖皮质激素受体β(GRß)和总 ERK(t-ERK)没有明显变化。HQH 与 DEX 或 PD98059 联合治疗增加了 Jurkat 和 Nalm-6 细胞的凋亡,同时增加了 BAX、cleaved-caspase-3、GILZ、NFKBIA 和 GRalpha,降低了 Bcl-2 和 pERK。
HQH 通过增加 GRalpha 的表达和抑制 MEK/ERK 通路,提高了 ALL 细胞对糖皮质激素的敏感性,为 HQH 治疗 ALL 提供了合理的基础。